- $2.46m
- $0.79m
- $0.13m
Brief: Organovo On Track To Establish Human 3D Disease Model In Inflammatory Bowel Disease In 2022
Brief: Organovo Holdings Inc - CFO Jonathan Lieber Notified Of His Intent To Resign, From His Part-Time Role To Pursue A Full-Time Opportunity
Brief: Organovo Holdings Inc - On April 13, CFO Chris Heberlig, Notified Company Of His Intent To Resign From Company, Effective May 7, 2021
Brief: Organovo Holdings- Entered Into Sales Agreement Relating To Up To $50 Million Shares Of Common Stock - SEC Filing
Brief: Organovo Holdings Files For Mixed Shelf Of Upto $150 Mln
NASDAQ RESUMED AT 11:22 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 11:17 AM
Brief: Organovo Regains Compliance With Nasdaq Minimum Bid Price Requirement
Brief: Organovo Announces Termination Of Merger Agreement With Tarveda Therapeutics
Brief: Keith Murphy Says Issued Statement Regarding Adjournment Of March 26 Special Meeting Of Organovo Stockholders
Brief: Viscient Biosciences Founder Keith Murphy Calls For Pause In Organovo Deal
Brief: Keith Murphy Sends Letter To Organovo Holdings Shareholders
Brief: Organovo Holdings Inc - Bioprinting And Similar Technologies Are Going Strong And Still Growing
Brief: Organovo Holdings Gets Additional 180 Days To Regain Compliance From Nasdaq
NASDAQ RESUMED AT 09:45 AM
U.S. STOCKS ON THE MOVE-PG&E, Boeing, Wave Life Sciences, Axsome Therapeutics
NASDAQ RESUMED AT 07:30 AM
Brief: Organovo And Tarveda Therapeutics Announce Definitive Merger Agreement
NASDAQ TRADE HALT HALT NEWS PENDING AT 06:57 AM